目的:评价桥本甲状腺炎(HT)对超声(US)引导下早期甲状腺乳头状微小癌(PTMC)射频消融(RFA)消融区范围的影响。
方法:我们选择了2017年8月至2020年8月接受RFA治疗的772例PTMC患者。他们分为以下两组:(i)“HTPTMC”组中的216例HT患者(224例PTMC)和(ii)“PTMC”组中的556例甲状腺健康患者(573例PTMC)组。我们立即通过对比增强超声(CEUS)评估消融区的范围(最大直径和体积),有一天,RFA后1周。
结果:在RFA治疗1周时,“HT+PTMC”组的消融区小于“PTMC”组的消融区(最大直径:14.6±3.1mmvs.15.2±3.2mm,体积:0.932±0.498mLvs.1.028±0.540mL,分别,p<.05)。然而,以前没有区别,立即,RFA后一天(p>0.05)。任何患者均未出现危及生命的并发症。
结论:在RFA治疗1周时,HT患者接受RFA治疗的PTMC的体积比甲状腺健康患者的小。然而,这种现象的确切机制及其临床意义值得进一步研究。
OBJECTIVE: To evaluate the effect of Hashimoto\'s thyroiditis (HT) on the extent of ablation zone in ultrasound (US)-guided radiofrequency ablation (RFA) for early stages of papillary thyroid microcarcinoma (PTMC).
METHODS: We selected 772 patients with 797 PTMCs who underwent with RFA from August 2017 to August 2020. They were subdivided into two groups as follows: (i) 216 patients (224 PTMCs) with HT in the \'HT + PTMC\' group and (ii) 556 patients (573 PTMCs) with healthy thyroid in the \'PTMC\' group. We assessed the extent (maximum diameter and volume) of the ablation zone by contrast-enhanced ultrasound (CEUS) immediately, one day, and 1 week following RFA.
RESULTS: The ablation zone of the \'HT + PTMC\' group was smaller than that of the \'PTMC\' group at 1 week of RFA (maximum diameter: 14.6 ± 3.1 mm vs. 15.2 ± 3.2 mm and volume: 0.932 ± 0.498 mL vs. 1.028 ± 0.540 mL, respectively, p < .05). However, there were no differences before, immediately, and one day post-RFA (p > .05). Life-threatening complications did not develop in any of the patients.
CONCLUSIONS: RFA-treated PTMCs were smaller in size in patients with HT than in those with a healthy thyroid at 1 week of RFA. However, the exact mechanism underlying this phenomenon and its clinical significance warrant further investigation.